Inspire Medical Systems, Inc. (NYSE:INSP) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Inspire Medical Systems, Inc. (NYSE:INSP) have been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $231.45.

Several equities research analysts have commented on the stock. Stifel Nicolaus dropped their price target on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating on the stock in a research report on Tuesday, January 21st. Royal Bank of Canada reiterated an “outperform” rating and set a $260.00 price target on shares of Inspire Medical Systems in a report on Tuesday, November 5th. KeyCorp restated an “overweight” rating and issued a $234.00 price objective (down previously from $236.00) on shares of Inspire Medical Systems in a research note on Friday, January 24th. Robert W. Baird lifted their target price on shares of Inspire Medical Systems from $240.00 to $252.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Finally, Bank of America raised shares of Inspire Medical Systems from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $220.00 to $255.00 in a research note on Wednesday, November 20th.

Inspire Medical Systems Trading Up 0.4 %

INSP stock opened at $182.00 on Friday. Inspire Medical Systems has a 12-month low of $123.00 and a 12-month high of $257.40. The company has a market cap of $5.45 billion, a price-to-earnings ratio of 170.10 and a beta of 1.32. The firm has a 50 day moving average of $189.94 and a 200-day moving average of $189.68.

Institutional Trading of Inspire Medical Systems

A number of institutional investors have recently made changes to their positions in the company. Wasatch Advisors LP lifted its position in Inspire Medical Systems by 1.6% in the third quarter. Wasatch Advisors LP now owns 1,323,470 shares of the company’s stock valued at $279,318,000 after acquiring an additional 20,481 shares during the last quarter. State Street Corp boosted its stake in shares of Inspire Medical Systems by 78.0% during the 3rd quarter. State Street Corp now owns 1,049,784 shares of the company’s stock worth $221,557,000 after purchasing an additional 459,990 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Inspire Medical Systems by 5.8% in the 3rd quarter. Janus Henderson Group PLC now owns 502,609 shares of the company’s stock worth $106,075,000 after buying an additional 27,374 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Inspire Medical Systems by 0.7% in the third quarter. Geode Capital Management LLC now owns 483,654 shares of the company’s stock worth $102,102,000 after acquiring an additional 3,128 shares in the last quarter. Finally, TimesSquare Capital Management LLC purchased a new position in Inspire Medical Systems in the 4th quarter worth approximately $80,419,000. 94.91% of the stock is owned by institutional investors and hedge funds.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.